Mersana Therapeutics, Inc. Total Contract Liability
Mersana Therapeutics, Inc. had Total Contract Liability of $102.72 million as of 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2025-11-14
- 2025-09-30: Contract with Customer, Liability $102.72M.
- 2025-06-30: Contract with Customer, Liability $98.56M.
- 2025-03-31: Contract with Customer, Liability $100.73M.
- 2024-12-31: Contract with Customer, Liability $101.63M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2025-09-30 | $102.72M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $98.56M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $100.73M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $101.63M 10-Q · filed 2025-11-14 |
| 2024-09-30 | $115.24M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $116.92M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $117.64M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $125.31M 10-Q · filed 2025-11-14 |
| 2023-09-30 | $133.10M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $134.70M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $144.35M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $147.65M 10-K · filed 2025-03-03 |
| 2022-09-30 | $132.34M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $37.91M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $42.20M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $3.94M 10-K · filed 2024-02-28 |
| 2021-09-30 | $3.96M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $3.97M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $3.98M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $3.99M 10-K · filed 2023-02-28 |
| 2020-09-30 | $4.00M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $4.01M 10-Q · filed 2021-08-06 |
| 2020-03-31 | $4.80M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $4.82M 10-K · filed 2022-02-28 |
| 2019-09-30 | $4.65M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $5.48M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $5.60M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $46.20M 10-K · filed 2021-02-26 |
| 2018-09-30 | $46.91M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $48.21M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $50.46M 10-Q · filed 2018-08-14 |
| 2017-12-31 | $52.44M 10-K · filed 2020-02-28 |